Zivo Bioscience Inc. Warrants (ZIVOW) - Net Assets
Based on the latest financial reports, Zivo Bioscience Inc. Warrants (ZIVOW) has net assets worth $327.67K USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($559.45K) and total liabilities ($231.79K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Zivo Bioscience Inc. Warrants debt and liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $327.67K |
| % of Total Assets | 58.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Zivo Bioscience Inc. Warrants - Net Assets Trend (2003–2024)
This chart illustrates how Zivo Bioscience Inc. Warrants's net assets have evolved over time, based on quarterly financial data. Also explore Zivo Bioscience Inc. Warrants asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Zivo Bioscience Inc. Warrants (2003–2024)
The table below shows the annual net assets of Zivo Bioscience Inc. Warrants from 2003 to 2024. For live valuation and market cap data, see Zivo Bioscience Inc. Warrants stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-514.90K | +76.66% |
| 2023-12-31 | $-2.21 Million | -20666.74% |
| 2022-12-31 | $-10.62K | -100.18% |
| 2021-12-31 | $6.04 Million | +153.42% |
| 2020-12-31 | $-11.31 Million | -35.64% |
| 2019-12-31 | $-8.34 Million | +62.58% |
| 2018-12-31 | $-22.28 Million | -36.66% |
| 2017-12-31 | $-16.30 Million | -19.70% |
| 2016-12-31 | $-13.62 Million | -43.43% |
| 2015-12-31 | $-9.50 Million | -49.11% |
| 2014-12-31 | $-6.37 Million | +33.61% |
| 2013-12-31 | $-9.59 Million | -142.50% |
| 2012-12-31 | $-3.96 Million | -94.74% |
| 2011-12-31 | $-2.03 Million | -113.46% |
| 2010-12-31 | $-951.68K | +74.86% |
| 2009-12-31 | $-3.79 Million | -628.57% |
| 2008-12-31 | $-519.60K | +31.21% |
| 2007-12-31 | $-755.37K | +9.27% |
| 2006-12-31 | $-832.54K | -41.09% |
| 2005-12-31 | $-590.09K | +46.48% |
| 2004-12-31 | $-1.10 Million | -2968.34% |
| 2003-12-31 | $-35.94K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zivo Bioscience Inc. Warrants's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13692220400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.62K | % |
| Other Components | $136.45 Million | % |
| Total Equity | $-514.90K | 100.00% |
Zivo Bioscience Inc. Warrants Competitors by Market Cap
The table below lists competitors of Zivo Bioscience Inc. Warrants ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Future Enterprises Limited
NSE:FEL
|
$46.22 |
|
Advantage Solutions Inc
NASDAQ:ADVWW
|
$46.28 |
|
Prairie Lithium Limited
AU:PL9
|
$49.49 |
|
RPCG PCL F
F:R4Q
|
$56.45 |
|
Katapult Holdings Equity Warrants Exp 09 June 2026
NASDAQ:KPLTW
|
$35.36 |
|
Liberty Metals Ltd
AU:LIB
|
$33.93 |
|
Reliance Global Group Inc
NASDAQ:RELIW
|
$33.88 |
|
Reviva Pharmaceuticals Holdings Inc
NASDAQ:RVPHW
|
$29.82 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zivo Bioscience Inc. Warrants's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,205,843 to -514,897, a change of 1,690,946.
- Net loss of 13,384,836 reduced equity.
- New share issuances of 5,602,269 increased equity.
- Other factors increased equity by 9,473,513.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.38 Million | -2599.52% |
| Share Issuances | $5.60 Million | +1088.04% |
| Other Changes | $9.47 Million | +1839.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Zivo Bioscience Inc. Warrants's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-0.17 | $0.01 | x |
| 2001-12-31 | $-4.92 | $0.01 | x |
| 2002-12-31 | $-2.64 | $0.01 | x |
| 2003-12-31 | $-0.30 | $0.01 | x |
| 2004-12-31 | $-7.75 | $0.01 | x |
| 2005-12-31 | $-2.59 | $0.01 | x |
| 2006-12-31 | $-1.94 | $0.01 | x |
| 2007-12-31 | $-1.43 | $0.01 | x |
| 2008-12-31 | $-0.79 | $0.01 | x |
| 2009-12-31 | $-4.11 | $0.01 | x |
| 2010-12-31 | $-0.87 | $0.01 | x |
| 2011-12-31 | $-1.68 | $0.01 | x |
| 2012-12-31 | $-18.73 | $0.01 | x |
| 2013-12-31 | $-41.04 | $0.01 | x |
| 2014-12-31 | $-16.78 | $0.01 | x |
| 2015-12-31 | $-34.81 | $0.01 | x |
| 2016-12-31 | $-48.85 | $0.01 | x |
| 2017-12-31 | $-56.20 | $0.01 | x |
| 2018-12-31 | $-68.26 | $0.01 | x |
| 2019-12-31 | $-14.48 | $0.01 | x |
| 2020-12-31 | $-13.37 | $0.01 | x |
| 2021-12-31 | $4.75 | $0.01 | x |
| 2022-12-31 | $-0.01 | $0.01 | x |
| 2023-12-31 | $-1.31 | $0.01 | x |
| 2024-12-31 | $-0.15 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zivo Bioscience Inc. Warrants utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8513.44%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-6.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.45K |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $2.51K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $1.48K |
| 2003 | 0.00% | -32191.49% | 0.17x | 0.00x | $-537.22K |
| 2004 | 0.00% | -7866.21% | 0.92x | 0.00x | $-3.75 Million |
| 2005 | 0.00% | -6207.23% | 0.15x | 0.00x | $-5.90 Million |
| 2006 | 0.00% | -1191.15% | 0.92x | 0.00x | $-3.46 Million |
| 2007 | 0.00% | -1395.18% | 0.59x | 0.00x | $-2.18 Million |
| 2008 | 0.00% | -1025.33% | 0.41x | 0.00x | $-1.76 Million |
| 2009 | 0.00% | -1790.32% | 0.20x | 0.00x | $-1.04 Million |
| 2010 | 0.00% | -8609.82% | 0.24x | 0.00x | $-7.03 Million |
| 2011 | 0.00% | -2629.30% | 0.22x | 0.00x | $-2.53 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.85 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.14 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $1.32 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.84 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.70 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.41 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.41 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.83 Million |
| 2020 | 0.00% | -48278.92% | 0.09x | 0.00x | $-8.52 Million |
| 2021 | -155.52% | 0.00% | 0.00x | 1.49x | $-10.00 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.74 Million |
| 2023 | 0.00% | -28127.25% | 0.05x | 0.00x | $-7.56 Million |
| 2024 | 0.00% | -8513.44% | 0.10x | 0.00x | $-13.33 Million |
Industry Comparison
This section compares Zivo Bioscience Inc. Warrants's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zivo Bioscience Inc. Warrants (ZIVOW) | $327.67K | 0.00% | 0.71x | $45.38 |
| Advent Technologies Holdings Inc (ADNWW) | $-1.79 Million | 0.00% | 0.00x | $26.11 |
| AmpliTech Group Inc (AMPGW) | $500.36K | -19.40% | 0.33x | $754.81 |
| Arko Corp (ARKOW) | $194.89 Million | -22.34% | 8.48x | $23.51 |
| Aris Mining Corporation (ARMN) | $216.71 Million | -1.53% | 1.14x | $3.93 Billion |
| Aberdeen Standard Global Infrastructure Income Fund (ASGI) | $482.92 Million | 1.71% | 0.01x | $472.62 Million |
| Atlas Corp (ATCOL) | $1.06 Billion | 13.71% | 2.46x | $240.21K |
| Auddia Inc (AUUDW) | $420.42K | -2094.93% | 9.47x | $398.90 |
| BriaCell Therapeutics Corp (BCTXW) | $-643.49K | 0.00% | 0.00x | $8.25 |
| Blaize Holdings, Inc. Warrants (BZAIW) | $24.24 Million | -252.48% | 0.99x | $4.00 Million |
| Churchill Capital Corp IX Warrant (CCIXW) | $288.99 Million | 3.04% | 0.04x | $14.04 Million |
About Zivo Bioscience Inc. Warrants
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more